

Andrew G Horti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8277685/publications.pdf>

Version: 2024-02-01

87
papers

3,394
citations

117625

34
h-index

155660

55
g-index

89
all docs

89
docs citations

89
times ranked

2724
citing authors

#	ARTICLE	IF	CITATIONS
1	PET/CT imaging of CSF1R in a mouse model of tuberculosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4088-4096.	6.4	1
2	¹⁸ F-labeled radiotracers for in vivo imaging of DREADD with positron emission tomography. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113047.	5.5	7
3	First-in-human neuroimaging of soluble epoxide hydrolase using [¹⁸ F]FNDP PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3122-3128.	6.4	6
4	High Availability of the $\alpha 7$ -Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ¹⁸ F-ASEM PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 423-426.	5.0	22
5	In Vitro and In Vivo Characterization of Dibenzothiophene Derivatives [¹²⁵ I]Iodo-ASEM and [¹⁸ F]ASEM as Radiotracers of Homo- and Heteromeric $\alpha 7$ Nicotinic Acetylcholine Receptors. <i>Molecules</i> , 2020, 25, 1425.	3.8	8
6	PET imaging of soluble epoxide hydrolase in non-human primate brain with [¹⁸ F]FNDP. <i>EJNMMI Research</i> , 2020, 10, 67.	2.5	10
7	Radiosynthesis and validation of [¹¹ C]methylpiperazine(4-((piperidin-1-yl)phenyl)furan-2-carboxamide) ([¹¹ C]CPPC), a PET radiotracer for imaging CSF1R, a microglia-specific marker. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 903-908.	1.0	10
8	High-potency ligands for DREADD imaging and activation in rodents and monkeys. <i>Nature Communications</i> , 2019, 10, 4627.	12.8	128
9	14.3 OPPORTUNITIES IN PRECISION PSYCHIATRY USING PET-BASED NEUROIMAGING. <i>Schizophrenia Bulletin</i> , 2019, 45, S111-S112.	4.3	0
10	23.4 PET-BASED PRECISION NEUROIMAGING OF THE ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR IN PATIENTS WITH RECENT ONSET OF PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S127-S127.	4.3	0
11	Opportunities in precision psychiatry using PET neuroimaging in psychosis. <i>Neurobiology of Disease</i> , 2019, 131, 104428.	4.4	8
12	Use of ¹⁸ F-ASEM PET to Determine the Availability of the $\alpha 7$ -Nicotinic Acetylcholine Receptor in Recent-Onset Psychosis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 241-243.	5.0	19
13	PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1686-1691.	7.1	140
14	Synthesis and Evaluation of a New ¹⁸ F-Labeled Radiotracer for Studying the GABAB Receptor in the Mouse Brain. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1453-1461.	3.5	7
15	¹⁸ F-XTRA PET for Enhanced Imaging of the Extrathalamic $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1603-1608.	5.0	15
16	An optimized radiosynthesis of [¹⁸ F]FNDP, a positron emission tomography radiotracer for imaging soluble epoxide hydrolase (sEH). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 567-572.	1.0	8
17	Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 320-332.	5.3	24
18	Brain PET Imaging of $\alpha 7$ -nAChR with [¹⁸ F]ASEM: Reproducibility, Occupancy, Receptor Density, and Changes in Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 656-667.	2.1	47

#	ARTICLE	IF	CITATIONS
19	The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM. <i>NeuroImage</i> , 2018, 165, 118-124.	4.2	27
20	Development of a radioligand for imaging V1a vasopressin receptors with PET. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 644-656.	5.5	8
21	Imaging $\alpha 7$ Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [18F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. <i>Molecular Imaging and Biology</i> , 2017, 19, 280-288.	2.6	11
22	Synthesis and Preliminary Biological Evaluation of Indol-3-yl-oxoacetamides as Potent Cannabinoid Receptor Type 2 Ligands. <i>Molecules</i> , 2017, 22, 77.	3.8	3
23	^{18}F -FNDP for PET Imaging of Soluble Epoxide Hydrolase. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1817-1822.	5.0	19
24	Development of a High-Affinity PET Radioligand for Imaging Cannabinoid Subtype 2 Receptor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7840-7855.	6.4	47
25	Development of Radiolabeled Ligands Targeting the Glutamate Binding Site of the $\text{N}^{\text{Methyl-D}}\text{-aspartate}$ Receptor as Potential Imaging Agents for Brain. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 11110-11119.	6.4	16
26	Microwave-assisted radiosynthesis of [^{18}F]ASEM, a radiolabeled $\alpha 7$ -nicotinic acetylcholine receptor antagonist. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2015, 58, 180-182.	1.0	10
27	Cannabinoid CB2 Receptors in a Mouse Model of $\text{A}\beta$ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. <i>PLoS ONE</i> , 2015, 10, e0129618.	2.5	83
28	Quantitative Multi-modal Brain Autoradiography of Glutamatergic, Dopaminergic, Cannabinoid, and Nicotinic Receptors in Mutant Disrupted-In-Schizophrenia-1 (DISC1) Mice. <i>Molecular Imaging and Biology</i> , 2015, 17, 355-363.	2.6	13
29	[^{125}I]Iodo-ASEM, a specific in vivo radioligand for $\alpha 7$ -nAChR. <i>Nuclear Medicine and Biology</i> , 2015, 42, 488-493.	0.6	8
30	Development of [^{18}F]ASEM, a specific radiotracer for quantification of the $\alpha 7$ -nAChR with positron-emission tomography. <i>Biochemical Pharmacology</i> , 2015, 97, 566-575.	4.4	31
31	AT-1001 Is a Partial Agonist with High Affinity and Selectivity at Human and Rat $\alpha 3$ and $\alpha 4$ Nicotinic Cholinergic Receptors. <i>Molecular Pharmacology</i> , 2015, 88, 640-649.	2.3	9
32	Brain PET Imaging in the Cannabinoid System. , 2014, , 27-36.		2
33	Human Brain Imaging of $\alpha 7$ nAChR with [18F]ASEM: a New PET Radiotracer for Neuropsychiatry and Determination of Drug Occupancy. <i>Molecular Imaging and Biology</i> , 2014, 16, 730-738.	2.6	69
34	^{18}F -ASEM, a Radiolabeled Antagonist for Imaging the $\alpha 7$ -Nicotinic Acetylcholine Receptor with PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 672-677.	5.0	65
35	Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. <i>Schizophrenia Research</i> , 2014, 159, 124-129.	2.0	52
36	PET Imaging of Endocannabinoid System. , 2014, , 249-319.		6

#	ARTICLE	IF	CITATIONS
37	Synthesis and evaluation of new radioligands [¹¹ C]A-833834 and [¹¹ C]A-752274 for positron-emission tomography of $\alpha 7$ -nicotinic acetylcholine receptors. <i>Nuclear Medicine and Biology</i> , 2013, 40, 395-402.	0.6	19
38	Derivatives of Dibenzothiophene for Positron Emission Tomography Imaging of $\alpha 7$ -Nicotinic Acetylcholine Receptors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7574-7589.	6.4	57
39	PET Imaging of High-Affinity $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptors in Humans with ¹⁸ F-AZAN, a Radioligand with Optimal Brain Kinetics. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1308-1314.	5.0	46
40	Recent PET radioligands with optimal brain kinetics for imaging nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 159-166.	1.0	24
41	PET Imaging of Nicotinic Acetylcholine Receptors in Baboons with ¹⁸ F-AZAN, a Radioligand with Improved Brain Kinetics. <i>Journal of Nuclear Medicine</i> , 2012, 53, 121-129.	5.0	32
42	5-(5-(6-[¹¹ C]methyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)-1H-indole as a potential PET radioligand for imaging cerebral $\alpha 7$ -nAChR in mice. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3698-3702.	3.0	9
43	Positron emission tomography experience with ¹⁸ F-fluoro- α -(2-(<i>s</i>) α -azetidinylmethoxy)pyridine (¹⁸ F)fa) in the living human brain of smokers with paranoid schizophrenia. <i>Synapse</i> , 2012, 66, 352-368.		28
44	Improved syntheses of precursors for PET radioligands [¹⁸ F]XTRA and [¹⁸ F]AZAN. <i>Tetrahedron Letters</i> , 2010, 51, 5333-5335.	1.4	8
45	Synthesis and biodistribution of [¹¹ C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 5202-5207.	3.0	93
46	Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [¹¹ C]OMAR. <i>NeuroImage</i> , 2010, 52, 1505-1513.	4.2	186
47	Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. <i>Life Sciences</i> , 2010, 86, 575-584.	4.3	54
48	Analogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): Development of ligands with optimized lipophilicity and binding affinity. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 593-608.	5.5	16
49	Synthesis and biological evaluation of novel carbon-11 labeled pyridyl ethers: candidate ligands for in vivo imaging of $\alpha 4\beta 2$ nicotinic acetylcholine receptors ($\alpha 4\beta 2$ -nAChRs) in the brain with positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 4367-4377.	3.0	11
50	Clinical Perspective and Recent Development of PET Radioligands for Imaging Cerebral Nicotinic Acetylcholine Receptors. <i>PET Clinics</i> , 2009, 4, 89-100.	3.0	20
51	New synthesis and evaluation of enantiomers of 7-methyl-2-exo-(3-iodo-5-pyridinyl)-7-azabicyclo[2.2.1]heptane as stereoselective ligands for PET imaging of nicotinic acetylcholine receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 6168-6170.	2.2	11
52	Discovery of (α)-7-Methyl-2-exo-[3-(6-(¹⁸ F)fluoropyridin-2-yl)-5-pyridinyl]-7-azabicyclo[2.2.1]heptane, a Radiolabeled Antagonist for Cerebral Nicotinic Acetylcholine Receptor ($\alpha 4\beta 2$ -nAChR) with Optimal Positron Emission Tomography Imaging Properties. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4751-4764.	6.4	34
53	Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with ¹⁸ F-FA-85380. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1628-1635.	5.0	126
54	Development of Radioligands for In Vivo Imaging of Type 1 Cannabinoid Receptors (CB1) in Human Brain. <i>Current Pharmaceutical Design</i> , 2008, 14, 3363-3383.	1.9	47

#	ARTICLE	IF	CITATIONS
55	Derivatives of (â ⁺)-7-Methyl-2-(5-(pyridinyl)pyridin-3-yl)-7-azabicyclo[2.2.1]heptane Are Potential Ligands for Positron Emission Tomography Imaging of Extrathalamic Nicotinic Acetylcholine Receptors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3814-3824.	6.4	14
56	6-Chloro-3-(((1-[11C]methyl)-2-(S)-pyrrolidinyl)methoxy)-5-(2-fluoropyridin-4-yl)pyridine ([11C]JHU85270), a potent ligand for nicotinic acetylcholine receptor imaging by positron emission tomography. <i>Applied Radiation and Isotopes</i> , 2007, 65, 947-951.	1.5	8
57	NIDA522131, a new radioligand for imaging extrathalamic nicotinic acetylcholine receptors: in vitro and in vivo evaluation. <i>Journal of Neurochemistry</i> , 2007, 104, 071106220615006-???	3.9	7
58	Radiosynthesis of the α 4 β 2 nicotinic acetylcholine receptor ligand: 5-((1-[11C]-methyl-2-(S)-pyrrolidinyl)methoxy)-2-chloro-3-((E)-2-(2-fluoropyridin-4-yl)vinyl)pyridine. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 459-462.	1.0	0
59	Synthesis of 2-[18F]fluoroadenosine (2-[18F]FAD) as potential radiotracer for studying malignancies by PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 811-815.	1.0	7
60	Synthesis of 1-(2,4-dichlorophenyl)-4-cyano-5-(4-[11C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11C]JHU75528) and 1-(2-bromophenyl)-4-cyano-5-(4-[11C]methoxyphenyl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide ([11C]JHU75575) as potential radioligands for PET imaging of cerebral cannabinoid receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 1021-1036.	1.0	32
61	The Quest for Eldorado: Development of Radioligands for In Vivo Imaging of Nicotinic Acetylcholine Receptors in Human Brain. <i>Current Pharmaceutical Design</i> , 2006, 12, 3877-900.	1.9	56
62	11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1689-96.	5.0	84
63	In vitro characterization of 6-[18F]fluoro-A-85380, a high-affinity ligand for α 4 β 2* nicotinic acetylcholine receptors. <i>Synapse</i> , 2005, 55, 89-97.	1.2	20
64	Pharmacological and Toxicological Evaluation of 2-Fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-F-A-85380), a Ligand for Imaging Cerebral Nicotinic Acetylcholine Receptors with Positron Emission Tomography. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 312, 355-365.	2.5	29
65	Synthesis and Structure-Activity Relationship of a Novel Series of Aminoalkylindoles with Potential for Imaging the Neuronal Cannabinoid Receptor by Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5813-5822.	6.4	38
66	Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. <i>Journal of Neurochemistry</i> , 2004, 91, 600-612.	3.9	19
67	Synthesis of 6-chloro-3-((2-(S)-azetidinyl)methoxy)-5-(2-[18F]fluoropyridin-4-yl)pyridine ([18F]NIDA) Tj ETQq1 1 0.784314 rgBT /Over PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2004, 47, 947-952.	1.0	12
68	5-Substituted Derivatives of 6-Halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-Halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with Low Picomolar Affinity for α 4 β 2 Nicotinic Acetylcholine Receptor and Wide Range of Lipophilicity: A Potential Probes for Imaging with Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 2453-2465.	6.4	62
69	Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1620-1629.	6.4	45
70	Pharmacology, toxicology, and radiation dosimetry evaluation of [123I]5-I-A-85380, a radioligand for in vivo imaging of cerebral neuronal nicotinic acetylcholine receptors in humans. <i>Drug Development Research</i> , 2003, 58, 149-168.	2.9	12
71	Synthesis of N-(piperidin-1-yl)-5-(4-methoxyphenyl)-1-(2-chlorophenyl)-4-[18F]fluoro-1H-pyrazole-3-carboxamide by nucleophilic [18F] fluorination: a PET radiotracer for studying CB1 cannabinoid receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 93-98.	1.0	20
72	Graphical analysis of 2-[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. <i>Synapse</i> , 2003, 48, 25-34.	1.2	81

#	ARTICLE	IF	CITATIONS
73	Synthesis, Structure-Activity Relationship, and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 642-645.	6.4	125
74	¹⁸ F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. <i>FASEB Journal</i> , 2003, 17, 1331-1333.	0.5	112
75	Synthesis and Evaluation of a Novel Series of 2-Chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine Analogues as Potential Positron Emission Tomography Imaging Agents for Nicotinic Acetylcholine Receptors. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2841-2849.	6.4	32
76	Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [¹²³ I]5-I-A-85380 in healthy human subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 183-190.	6.4	56
77	Radiosynthesis of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-[¹¹ C]methyl-2-(S)-pyrrolidinylmethoxy)pyridine, a high affinity ligand for studying nicotinic acetylcholine receptors by positron emission tomography. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 3055-3058.	3.0	8
78	5-Iodo-A-85380, an $\alpha 4\beta 2$ Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors. <i>Molecular Pharmacology</i> , 2000, 57, 642-649.	2.3	167
79	6-[¹⁸ F]fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. <i>Nuclear Medicine and Biology</i> , 2000, 27, 51-56.	0.6	48
80	6-[¹⁸ F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. <i>Life Sciences</i> , 2000, 67, 463-469.	4.3	49
81	Radiosynthesis and preliminary evaluation of 5-[¹²³ I/ ¹²⁵ I]iodo-3-(2(S)-azetidylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors. <i>Nuclear Medicine and Biology</i> , 1999, 26, 175-182.	0.6	50
82	2-[¹⁸ F]F-A-85380. <i>NeuroReport</i> , 1999, 10, 2715-2721.	1.2	45
83	2-, 5-, and 6-Halo-3-(2(S)-azetidylmethoxy)pyridines: Synthesis, Affinity for Nicotinic Acetylcholine Receptors, and Molecular Modeling. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 3690-3698.	6.4	129
84	Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: 2-[¹⁸ F]fluoro-3-(2(S)-azetidylmethoxy)pyridine (2-[¹⁸ F]A-85380). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1998, 41, 309-318.	1.0	56
85	2-[¹⁸ F]fluoro-A-85380, an in vivo tracer for the nicotinic acetylcholine receptors. <i>Nuclear Medicine and Biology</i> , 1998, 25, 599-603.	0.6	79
86	Synthesis and Evaluation of N-[¹¹ C]Methylated Analogues of Epibatidine as Tracers for Positron Emission Tomographic Studies of Nicotinic Acetylcholine Receptors. <i>Journal of Medicinal Chemistry</i> , 1998, 41, 4199-4206.	6.4	59
87	Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: (+)-exo-2-(2-[¹⁸ F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1996, 38, 355-365.	1.0	67